Despite the evidence favoring this new paradigm of complement anaphylatoxin-supported tumor progression under defined experimental conditions, it is premature to infer that targeting C3aR and C5aR would be an appropriate adjuvant antitumor strategy. The gene discussed is C3AR1; the disease is neoplasm.